299 related articles for article (PubMed ID: 21048992)
1. Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson's disease-linked mutants.
Roodveldt C; Labrador-Garrido A; Gonzalez-Rey E; Fernandez-Montesinos R; Caro M; Lachaud CC; Waudby CA; Delgado M; Dobson CM; Pozo D
PLoS One; 2010 Oct; 5(10):e13481. PubMed ID: 21048992
[TBL] [Abstract][Full Text] [Related]
2. FcγRIIB mediates the inhibitory effect of aggregated α-synuclein on microglial phagocytosis.
Choi YR; Kang SJ; Kim JM; Lee SJ; Jou I; Joe EH; Park SM
Neurobiol Dis; 2015 Nov; 83():90-9. PubMed ID: 26342897
[TBL] [Abstract][Full Text] [Related]
3. Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alpha-synuclein: implications for Parkinson's disease.
Park JY; Paik SR; Jou I; Park SM
Glia; 2008 Aug; 56(11):1215-23. PubMed ID: 18449945
[TBL] [Abstract][Full Text] [Related]
4. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.
Lee MK; Stirling W; Xu Y; Xu X; Qui D; Mandir AS; Dawson TM; Copeland NG; Jenkins NA; Price DL
Proc Natl Acad Sci U S A; 2002 Jun; 99(13):8968-73. PubMed ID: 12084935
[TBL] [Abstract][Full Text] [Related]
5. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS
J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873
[TBL] [Abstract][Full Text] [Related]
6. Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease.
Theodore S; Cao S; McLean PJ; Standaert DG
J Neuropathol Exp Neurol; 2008 Dec; 67(12):1149-58. PubMed ID: 19018246
[TBL] [Abstract][Full Text] [Related]
7. Preconditioning of microglia by α-synuclein strongly affects the response induced by toll-like receptor (TLR) stimulation.
Roodveldt C; Labrador-Garrido A; Gonzalez-Rey E; Lachaud CC; Guilliams T; Fernandez-Montesinos R; Benitez-Rondan A; Robledo G; Hmadcha A; Delgado M; Dobson CM; Pozo D
PLoS One; 2013; 8(11):e79160. PubMed ID: 24236103
[TBL] [Abstract][Full Text] [Related]
8. Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease.
Reynolds AD; Glanzer JG; Kadiu I; Ricardo-Dukelow M; Chaudhuri A; Ciborowski P; Cerny R; Gelman B; Thomas MP; Mosley RL; Gendelman HE
J Neurochem; 2008 Mar; 104(6):1504-25. PubMed ID: 18036154
[TBL] [Abstract][Full Text] [Related]
9. Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.
Gao HM; Zhang F; Zhou H; Kam W; Wilson B; Hong JS
Environ Health Perspect; 2011 Jun; 119(6):807-14. PubMed ID: 21245015
[TBL] [Abstract][Full Text] [Related]
10. Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease.
Allen Reish HE; Standaert DG
J Parkinsons Dis; 2015; 5(1):1-19. PubMed ID: 25588354
[TBL] [Abstract][Full Text] [Related]
11. Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease.
Gardai SJ; Mao W; Schüle B; Babcock M; Schoebel S; Lorenzana C; Alexander J; Kim S; Glick H; Hilton K; Fitzgerald JK; Buttini M; Chiou SS; McConlogue L; Anderson JP; Schenk DB; Bard F; Langston JW; Yednock T; Johnston JA
PLoS One; 2013; 8(8):e71634. PubMed ID: 24058406
[TBL] [Abstract][Full Text] [Related]
12. Fractalkine Signaling Regulates the Inflammatory Response in an α-Synuclein Model of Parkinson Disease.
Thome AD; Standaert DG; Harms AS
PLoS One; 2015; 10(10):e0140566. PubMed ID: 26469270
[TBL] [Abstract][Full Text] [Related]
13. Immunological features of alpha-synuclein in Parkinson's disease.
Roodveldt C; Christodoulou J; Dobson CM
J Cell Mol Med; 2008 Oct; 12(5B):1820-9. PubMed ID: 18671754
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.
Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN
J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665
[TBL] [Abstract][Full Text] [Related]
15. Nitrated {alpha}-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets.
Reynolds AD; Stone DK; Mosley RL; Gendelman HE
J Immunol; 2009 Apr; 182(7):4137-49. PubMed ID: 19299711
[TBL] [Abstract][Full Text] [Related]
16. Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.
Castro-Sánchez S; García-Yagüe ÁJ; López-Royo T; Casarejos M; Lanciego JL; Lastres-Becker I
Glia; 2018 Aug; 66(8):1752-1762. PubMed ID: 29624735
[TBL] [Abstract][Full Text] [Related]
17. [Role of microglial activation induced by α-synuclein in pathogenesis of Parkinson's disease].
Qiao S; Luo JH; Jin JH
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Mar; 41(2):210-4. PubMed ID: 22499522
[TBL] [Abstract][Full Text] [Related]
18. P2X7 receptor is critical in α-synuclein--mediated microglial NADPH oxidase activation.
Jiang T; Hoekstra J; Heng X; Kang W; Ding J; Liu J; Chen S; Zhang J
Neurobiol Aging; 2015 Jul; 36(7):2304-2318. PubMed ID: 25983062
[TBL] [Abstract][Full Text] [Related]
19. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death.
Martin LJ; Pan Y; Price AC; Sterling W; Copeland NG; Jenkins NA; Price DL; Lee MK
J Neurosci; 2006 Jan; 26(1):41-50. PubMed ID: 16399671
[TBL] [Abstract][Full Text] [Related]
20. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease.
Zhang W; Wang T; Pei Z; Miller DS; Wu X; Block ML; Wilson B; Zhang W; Zhou Y; Hong JS; Zhang J
FASEB J; 2005 Apr; 19(6):533-42. PubMed ID: 15791003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
